Enabling High Quality Cancer Imaging Trials in Ontario

Globally, there are a number of PET agents that are used in cancer diagnosis, staging and therapy monitoring, which to date have not been available in Ontario. These agents are in demand by Ontario researchers and clinicians as tools to evaluate new therapies, probe disease pathways and to enhance patient care. The specific aim is to build on the CPDC quality, regulatory and production programs (vide infra) to ensure that these agents are available to imaging programs in the Province. More specifically, the CPDC will seek approval for one new MI probe per year in support of cancer clinical trials in Ontario. The CPDC will use the ISRP program to create a mechanism for researchers and clinicians to request access to existing MI probes.